Mibg (123i) Curium Netherlands

Iobenguane I-123, the active ingredient in Mibg (123i) Curium Netherlands, is a radiopharmaceutical presented as a solution for injection for intravenous use. It enables visualization of sympathetic nervous system activity for diagnosis of adrenal medullary tumors, neuroblastoma, and related disorders in patients requiring functional imaging.

GNH USA supplies Mibg (123i) Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and clinics worldwide.

Mibg (123i) Curium Netherlands is used in diagnostic imaging of conditions involving adrenergic tissue activity.

Adrenal medullary tumors (e.g., pheochromocytoma): enables detection and precise localization of tumor tissue using scintigraphy. Neuroblastoma: provides functional imaging to assess tumor extent and response to therapy. Sympathetic nervous system disorders: visualizes abnormal sympathetic innervation patterns for diagnostic evaluation.

Adverse reactions may occur following intravenous injection of Iobenguane I-123.

Common Side Effects: - Nausea: mild, transient feeling of stomach upset. - Flushing: temporary reddening of skin, often on the face. - Headache: mild to moderate intensity. - Injection site pain: brief discomfort at the venipuncture site. - Transient hypertension: short‑lived rise in blood pressure. - Dizziness: mild light‑headedness.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or swelling that may progress to anaphylaxis. - Severe hypotension: marked drop in blood pressure requiring medical intervention. - Radiation‑induced tissue injury: rare localized damage at high cumulative doses. - Thyroid dysfunction: abnormal thyroid hormone levels due to iodine exposure. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals. - Severe anaphylactic shock: life‑threatening systemic allergic response.

Use of Iobenguane I-123 requires careful consideration of patient safety and handling requirements.

Pregnancy: avoid unless the diagnostic benefit outweighs potential fetal radiation risk. Breastfeeding: discontinue nursing or choose an alternative if possible. Renal impairment: assess renal function as reduced clearance may increase radiation exposure. Thyroid function: monitor thyroid status because of iodine content. Radiation safety: follow local regulations for handling and disposal of radioactive materials. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iobenguane I-123 may interact with drugs that affect norepinephrine transport or iodine metabolism.

Major Interactions (Avoid): - Norepinephrine transporter inhibitors (e.g., reserpine, certain antidepressants): may markedly reduce tracer uptake. - Thyroid blocking agents (e.g., potassium iodide): may alter tracer distribution and imaging quality.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may affect hemodynamic response during imaging. - Sympathomimetic agents (e.g., epinephrine): may compete for NET and reduce tracer accumulation. - Diuretics or other renal‑clearing drugs: may modify tracer clearance and background activity.